Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.
2026-08-26 10:20
•Dave Kovaleski •The Motley Fool
••• •• Axe Cap view
Ken Griffin's Bold Bet on AbbVie Highlights Appeal of Defensive Dividends
Citadel’s massive stake ramp-up in AbbVie underscores demand for reliable dividend income amid global uncertainty.
Ken Griffin’s Citadel nearly sextupled its position in AbbVie during Q2, signaling a strong vote of confidence in stable dividends and pharmaceutical resilience. AbbVie, a Dividend King with an unbroken 54-year streak of rising payouts, yields 2.6%—a healthy cushion in today’s volatile markets. For South African investors, AbbVie stands out as a proxy to defensive exposure beyond local cyclical sectors, especially as our rand remains sensitive to global risk events. Its forward valuation of 18 times earnings and a low PEG (price/earnings to growth) ratio suggest the market has not run away from value here. Local banks and retailers, from Standard Bank to Shoprite, may not offer the same defensive qualities amid domestic economic pressure. AbbVie’s cash flow and pipeline stability provide some insulation against global shocks. That said, currency moves like a stronger rand or USD weakness could make this less attractive in ZAR terms. If AbbVie’s drug pipeline stumbles or regulation tightens sharply, this view falls apart. this is just our opinion and not financial advice
Allocate a modest portion of offshore slots to AbbVie as a ballast against rand volatility and local economic risk. Avoid increasing exposure until currency and global rates stabilize.
- USD/ZAR
- ABBV
- Stronger rand reduces offshore earnings in local terms
- Pharmaceutical regulatory setbacks or pipeline failures
6/10
Billionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.
Our take is based on reporting first published by The Motley Fool.
More stories like this
- Billionaire David Tepper Sold Every Single Share of UnitedHealth in Q2. Here's Whether He Made a Costly Mistake.
- SpaceX Just Announced a $100 Billion Starship Spaceport in Louisiana. Here's What It Means for Investors.
- The Stock Market Faces a Critical Test on Wednesday -- Nvidia Earnings, Inflation, and GDP on the Same Day. Here’s What Investors Need to Know.